Drug Profile
Research programme: TRPV1 receptor agonists - Medifron
Alternative Names: MDR-652Latest Information Update: 20 Jun 2022
Price :
$50
*
At a glance
- Originator Digital Biotech
- Developer Medifron DBT
- Class Analgesics
- Mechanism of Action TRPV1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic neuropathies; Postherpetic neuralgia
Most Recent Events
- 16 Jun 2022 Preclinical development in Diabetic-neuropathies is still underway in South Korea (Transdermal)
- 16 Jun 2022 Preclinical development in Postherpetic-neuralgia is still underway in South Korea (Transdermal)
- 31 Dec 2020 Korea Food and Drug Administration (KFDA) approves the IND application for MDR 652 for Neuropathic pain